Six-probe scintillator dosimeter for treatment verification in HDR-brachytherapy.

BACKGROUND: In vivo dosimetry (IVD) is gaining interest for treatment delivery verification in HDR-brachytherapy. Time resolved methods, including source tracking, have the ability both to detect treatment errors in real time and to minimize experimental uncertainties. Multiprobe IVD architectures holds promise for simultaneous dose determinations at the targeted tumor and surrounding healthy tissues while enhancing measurement accuracy. However, most of the multiprobe dosimeters developed so far either suffer from compactness issues or rely on complex data post-treatment. PURPOSE: We introduce a novel concept of a compact multiprobe scintillator detector and demonstrate its applicability in HDR-brachytherapy. Our fabricated seven-fiber probing system is sufficiently narrow to be inserted in a brachytherapy needle or in a catheter. METHODS: Our multiprobe detection system results from the parallel implementation of six miniaturized inorganic Gd2 O2 S:Tb scintillator detectors at the end of a bundle of seven fibers, one fiber is kept bare to assess the stem effect. The resulting system, which is narrower than 320 microns, is tested with a MicroSelectron 9.14 Ci Ir-192 HDR afterloader, in a water phantom. The detection signals from all six probes are simultaneously read with a sCMOS camera (at a rate of 0.06 s). The camera is coupled to a chromatic filter to cancel Cerenkov signal induced within the fibers upon exposure. By implementing an aperiodic array of six scintillating cells along the bundle axis, we first determine the range of inter-probe spacings leading to optimal source tracking accuracy (first tracking method). Then, three different source tracking algorithms involving all the scintillating probes are tested and compared. In each of these four methods, dwell positions are assessed from dose measurements and compared to the treatment plan. Dwell time is also determined and compared to the treatment plan. RESULTS: The optimum inter-probe spacing for an accurate source tracking ranges from 15 to 35 mm. The optimum detection algorithm consists of adding the readout signals from all detector probes. In that case, the error to the planned dwell positions is of 0.01 ± 0.14 mm and 0.02 ± 0.29 mm at spacings between the source and detector axes of 5.5 and 40 mm, respectively. Using this approach, the average deviations to the expected dwell time are of - 0.006 ± 0.009 $-0.006\,\pm \,0.009$ s and - 0.008 ± 0.058 $-0.008\, \pm 0.058$ s, at spacings between source and probe axes of 5.5 and 20 mm, respectively. CONCLUSIONS: Our six-probe Gd2 O2 S:Tb dosimeter coupled to a sCMOS camera can perform time-resolved treatment verification in HDR brachytherapy. This detection system of high spatial and temporal resolutions (0.25 mm and 0.06 s, respectively) provides a precise information on the treatment delivery via a dwell time and position verification of unmatched accuracy.

Online adaptive radiotherapy and dose delivery accuracy: A retrospective analysis.

PURPOSE: With online adaptive radiotherapy (ART), patient-specific quality assurance (PSQA) testing cannot be performed prior to delivery of the adapted treatment plan. Consequently, the dose delivery accuracy of adapted plans (i.e., the ability of the system to interpret and deliver the treatment as planned) are not initially verified. We investigated the variation in dose delivery accuracy of ART on the MRIdian 0.35 T MR-linac (Viewray Inc., Oakwood, USA) between initial plans and their respective adapted plans, by analyzing PSQA results. METHODS: We considered the two main digestive localizations treated with ART (liver and pancreas). A total of 124 PSQA results acquired with the ArcCHECK (Sun Nuclear Corporation, Melbourne, USA) multidetector system were analyzed. PSQA result variations between the initial plans and their respective adapted plans were statistically investigated and compared with the variation in MU number. RESULTS: For the liver, limited deterioration in PSQA results was observed, and was within the limits of clinical tolerance (Initial = 98.2%, Adapted = 98.2%, p = 0.4503). For pancreas plans, only a few significant deteriorations extending beyond the limits of clinical tolerance were observed and were due to specific, complex anatomical configurations (Initial = 97.3%, Adapted = 96.5%, p = 0.0721). In parallel, we observed an influence of the increase in MU number on the PSQA results. CONCLUSION: We show that the dose delivery accuracy of adapted plans, in terms of PSQA results, is preserved in ART processes on the 0.35 T MR-linac. Respecting good practices, and minimizing the increase in MU number can help to preserve the accuracy of delivery of adapted plans as compared to their respective initial plans.

Deep learning application for abdominal organs segmentation on 0.35 T MR-Linac images.

Introduction: Linear accelerator (linac) incorporating a magnetic resonance (MR) imaging device providing enhanced soft tissue contrast is particularly suited for abdominal radiation therapy. In particular, accurate segmentation for abdominal tumors and organs at risk (OARs) required for the treatment planning is becoming possible. Currently, this segmentation is performed manually by radiation oncologists. This process is very time consuming and subject to inter and intra operator variabilities. In this work, deep learning based automatic segmentation solutions were investigated for abdominal OARs on 0.35 T MR-images. Methods: One hundred and twenty one sets of abdominal MR images and their corresponding ground truth segmentations were collected and used for this work. The OARs of interest included the liver, the kidneys, the spinal cord, the stomach and the duodenum. Several UNet based models have been trained in 2D (the Classical UNet, the ResAttention UNet, the EfficientNet UNet, and the nnUNet). The best model was then trained with a 3D strategy in order to investigate possible improvements. Geometrical metrics such as Dice Similarity Coefficient (DSC), Intersection over Union (IoU), Hausdorff Distance (HD) and analysis of the calculated volumes (thanks to Bland-Altman plot) were performed to evaluate the results. Results: The nnUNet trained in 3D mode achieved the best performance, with DSC scores for the liver, the kidneys, the spinal cord, the stomach, and the duodenum of 0.96 ± 0.01, 0.91 ± 0.02, 0.91 ± 0.01, 0.83 ± 0.10, and 0.69 ± 0.15, respectively. The matching IoU scores were 0.92 ± 0.01, 0.84 ± 0.04, 0.84 ± 0.02, 0.54 ± 0.16 and 0.72 ± 0.13. The corresponding HD scores were 13.0 ± 6.0 mm, 16.0 ± 6.6 mm, 3.3 ± 0.7 mm, 35.0 ± 33.0 mm, and 42.0 ± 24.0 mm. The analysis of the calculated volumes followed the same behavior. Discussion: Although the segmentation results for the duodenum were not optimal, these findings imply a potential clinical application of the 3D nnUNet model for the segmentation of abdominal OARs for images from 0.35 T MR-Linac.

Characterisation of a split gradient coil design induced systemic imaging artefact on 0.35 T MR-linac systems.

Objective. The aim of this work was to highlight and characterize a systemic 'star-like' artefact inherent to the low field 0.35 T MRIdian MR-linac system, a magnetic resonance guided radiotherapy device. This artefact is induced by the original split gradients coils design. This design causes a surjection of the intensity gradient inZ(or head-feet) direction. This artefact appears on every sequence with phase encoding in the head-feet direction.Approach. Basic gradient echo sequence and clinical mandatory bSSFP sequence were used. Three setups using manufacturer provided QA phantoms were designed: two including the linearity control grid used for the characterisation and a third including two homogeneity control spheres dedicated to the artefact management in a more clinical like situation. The presence of the artefact was checked in four different MRidian sites. The tested parameters based on the literature were: phase encoding orientation, slab selectivity, excitation bandwidth (BWRF), acceleration factor (R) and phase/slab oversampling (PO/SO).Main results. The position of this artefact is constant and reproducible over the tested MRIdian sites. The typical singularity saturated dot or star is visible even with the 3D slab-selection enabled. A management is proposed by decreasing the BWRF, theRin head-feet direction and increasing the PO/SO. The oversampling can be optimized using a formula to anticipate the location of artefact in the field of view.Significance. The star-like artefact has been well characterised. A manageable solution comes at the cost of acquisition time. Observed in clinical cases, the artefact may degrade the images used for the RT planning and repositioning during the treatment unless corrected.

Characterization of a miniaturized scintillator detector for time-resolved treatment monitoring in HDR-brachytherapy.

Purpose.HDR brachytherapy combines steep dose gradients in space and time, thereby requiring detectors of high spatial and temporal resolution to perform accurate treatment monitoring. We demonstrate a miniaturized fiber-integrated scintillator detector (MSD) of unmatched compactness which fulfills these conditions.Methods.The MSD consists of a 0.28 mm large and 0.43 mm long detection cell (Gd2O2S:Tb) coupled to a 110 micron outer diameter silica optical fiber. The fiber probe is tested in a phantom using a MicroSelectron 9.1 Ci Ir-192 HDR afterloader. The detection signal is acquired at a rate of 0.08 s with a standard sCMOS camera coupled to a chromatic filter (to cancel spurious Cerenkov signal). The dwell position and time monitoring are analyzed over prostate treatment sequences with dwell times spanning from 0.1 to 11 s. The dose rate at the probe position is both evaluated from a direct measurement and by reconstruction from the measured dwell position using the AAPM TG-43 formalism.Results.A total number of 1384 dwell positions are analyzed. In average, the measured dwell positions differ by 0.023 ± 0.077 mm from planned values over a 6-54 mm source-probe distance range. The standard deviation of the measured dwell positions is below 0.8 mm. 94% of the 966 dwell positions occurring at a source-probe inter-catheter spacing below 20 mm are successfully identified, with a 100% detection rate for dwell times exceeding 0.5 s. The average deviation to the planned dwell times is of 0.005 ± 0.060 s. The instant dose retrieval from dwell position monitoring leads to a relative mismatch to planned values of 0.14% ± 0.7%.Conclusion.A miniaturized Gd2O2S:Tb detector coupled to a standard sCMOS camera can be used for time-resolved treatment monitoring in HDR Brachytherapy.

Evaluation of QA software system analysis for the static picket fence test.

Intensity modulation treatments are widely used in radiotherapy because of many known advantages. In this context, the picket fence test (PF) is a relevant test to check the Multileaf Collimator (MLC) performances. So this work compares and evaluates three analysis platforms for the PF used routinely by three different institutions. This study covers two linear accelerators (Linac) with two MLC types, a Millenium 120 MLC and Millenium 120 High Definition MLC respectively on a Varian Truebeam and Truebeam STx. Both linacs include an As 1200 portal imager (EPID). From a reference PF plan, MLC errors have been introduced to modify the slits in position or width (shifts from 0.1 to 0.5 mm on one or both banks). Then errors have been defined on the EPID to investigate detection system deviations (signal sensitivity and position variations). Finally, 110 DICOM-RT images have been generated and analyzed by each software system. All software systems have shown good performances to quantify the position errors, even though the leaf pair identifications can be wrong in some cases regarding the analysis method considered. The slit width measurement (not calculated by all software systems) has shown good sensitivity, but some quantification difficulties have been highlighted regardless of the analysis method used. Linked to the expected accuracy of the PF test, the imager variations have demonstrated considerable influence in the results. Differences in the results and the analysis methods have been pointed out for each software system. The results can be helpful to optimize the settings of each analysis software system depending on expectations and treatment modalities of each institution.

Miniaturized scintillator dosimeter for small field radiation therapy.

The concept of a miniaturized inorganic scintillator detector is demonstrated in the analysis of the small static photon fields used in external radiation therapy. Such a detector is constituted by a 0.25 mm diameter and 0.48 mm long inorganic scintillating cell (1.6 × 10-5cm3detection volume) efficiently coupled to a narrow 125µm diameter silica optical fiber using a tiny photonic interface (an optical antenna). The response of our miniaturized scintillator detector (MSD) under 6 MV bremsstrahlung beam of various sizes (from 1 × 1 cm2to 4 × 4 cm2) is compared to that of two high resolution reference probes, namely, a micro-diamond detector and a dedicated silicon diode. The spurious Cerenkov signal transmitted through our bare detector is rejected with a basic spectral filtering. The MSD shows a linear response regarding the dose, a repeatability within 0.1% and a radial directional dependence of 0.36% (standard deviations). Beam profiling at 5 cm depth with the MSD and the micro-diamond detector shows a mismatch in the measurement of the full widths at 80% and 50% of the maximum which does not exceed 0.25 mm. The same difference range is found between the micro-diamond detector and a silicon diode. The deviation of the percentage depth dose between the MSD and micro-diamond detector remains below 2.3% within the first fifteen centimeters of the decay region for field sizes of 1 × 1 cm2, 2 × 2 cm2and 3 × 3 cm2(0.76% between the silicon diode and the micro-diamond in the same field range). The 2D dose mapping of a 0.6 × 0.6 cm2photon field evidences the strong 3D character of the radiation-matter interaction in small photon field regime. From a beam-probe convolution theory, we predict that our probe overestimates the beam width by 0.06%, making our detector a right compromise between high resolution, compactness, flexibility and ease of use. The MSD overcomes problem of volume averaging, stem effects, and despite its water non-equivalence it is expected to minimize electron fluence perturbation due to its extreme compactness. Such a detector thus has the potential to become a valuable dose verification tool in small field radiation therapy, and by extension in Brachytherapy, FLASH-radiotherapy and microbeam radiation therapy.

Patterns of Failure in Patients With Head and Neck Squamous Cell Carcinomas of Unknown Primary Treated With Chemoradiotherapy.

BACKGROUND: To evaluate the patterns of failure in patients treated for head and neck carcinoma of unknown primary and to discuss treatment practices concerning radiotherapy target volumes definition and dose prescription. METHODS: Eleven patients presenting a locoregional recurrence after head and neck carcinoma of unknown primary treatment with curative-intent radiochemotherapy performed between 2007 and 2017 in the departments of radiation oncology of 2 French cancer institutes. Images of the computed tomography scan or the magnetic resonance imaging performed at the time of the recurrence were fused with those of the simulation computed tomography scan to delimit a volume corresponding to the recurrence and to define the area of relapse compared to the volumes treated. RESULTS: Irradiation was unilateral in 6 cases and bilateral in 5 cases. The median time to onset of recurrence was 7.24 months (extreme 3-67.7 months). Six patients had only a neck node recurrence, 3 had a neck node and subsequent primary recurrence, and 1 had only a median subsequent primary recurrence. Only 1 patient had synchronous distance progression to local recurrence. All neck node recurrences were solitary and ipsilateral. The subsequent primary recurrences were in the oropharynx in 3 cases and in the contralateral oral cavity in one case. All neck node recurrences were into the irradiated volume. The subsequent primary recurrences were either within or in border of the irradiated volumes. The median of the mean dose, received by neck node recurrences, was 69.9 Gy and that of the mean dose, minimum dose, maximum dose, and dose received by 95% of the volume of recurrence was 66.7 Gy. For the primary relapses, the median of the mean dose was 52.1 Gy and that of the mean dose, minimum dose, maximum dose, and dose received by 95% of the volume of recurrence was 39.9 Gy. CONCLUSIONS: All local nodal recurrences occurred at sites that received high radiotherapy doses and doses received by sites of eventual failure did not vary significantly from sites that remain in control.

Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer.

PURPOSE: The concept of metastasis-directed therapy for nodal oligorecurrences with stereotactic body radiotherapy is increasingly accepted. Hence, the comparison between salvage extended field radiotherapy (s-EFRT) and salvage involved field radiotherapy (s-IFRT) in patients with 18F-fluorocholine (FCH) PET/CT+ nodal oligorecurrences from prostate cancer is worthy of investigation. METHODS: Patients with oligorecurrent nodes on FCH PET/CT treated with salvage radiotherapy between 2009 and 2017 in a single tertiary cancer centre were selected for this study. Patients treated with s-IFRT were compared with those treated with s-EFRT. Toxicities and times to failure (TTF) were compared between the two groups. RESULTS: The study included 62 patients with positive lymph nodes only who underwent FCH PET/CT for a rising PSA level after radical prostatectomy or radiotherapy. Of these patients, 35 had s-IFRT and 27 had s-EFRT. After a median follow-up of 41.8 months (range 5.9-108.1 months), no differences were observed in acute or late gastrointestinal and genitourinary toxicities of grade 2 or more between the two groups. The 3-year failure rates were 55.3% (95% CI 37.0-70.3%) in the s-IFRT group and 88.3% (95% CI 66.9-96.1%) in the s-EFRT group (p = 0.0094). In multivariate analysis of TTF, an interval of >5 years was significantly correlated with better outcomes (HR = 0.33, 95% CI 0.13-0.86, p = 0.023). There was a strong trend toward better outcomes with s-EFRT even after adjusting for concomitant androgen-deprivation therapy (HR = 0.38, 95% CI 0.12-1.27, p = 0.116). CONCLUSION: FCH PET-positive node-targeted s-EFRT is feasible with low rates of toxicity and longer TTF, suggesting that oligorecurrent nodal disease diagnosed on FCH PET is unlikely.

Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy.

BACKGROUND AND PURPOSE: We aimed to compare three-dimensional conformal radiotherapy (3D-CRT) with intensity-modulated radiotherapy (IMRT) for the treatment of glioblastoma. MATERIALS AND METHODS: Retrospective study of 220 patients with glioblastoma, treated with 3D-CRT or IMRT, with or without surgery. Dosimetric parameters as well as clinical and survival data for the two techniques were analyzed and compared. RESULTS: The median conformity index was 1.53 (range 0-2.69) for 3D-CRT and 1.25 (range 0.97-2.01) for IMRT, p < 10-4. The median homogeneity index was 0.10 (range 0.03-0.32) for 3D-CRT and 0.07 (range 0.03-0.18) for IMRT, p < 10-4. There were significantly fewer acute grade 1 and 2 neurological toxicities in the IMRT group especially for edema (1.3 versus 12.4%, p = 0.017), concentration disorders (6.6 versus 19.9%, p = 0.003) and consciousness disorders (2.6 versus 13.2%, p = 0.002) although IMRT patients had a significantly worse pre-treatment neurological status than 3D-CRT patients. Median survival was 16.0 months (range 11.9-17.8) for IMRT and 13.4 months (range 11.7-15.7) for 3D-CRT patients (p = 0.542). CONCLUSION: IMRT improved target conformity and reduced neurological toxicities for patients with glioblastomas.